

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandra, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/027,267	12/21/2001	Dennis Stein Everhart		16,540	3116
23556 7.	590 04/05/2004			EXAMINER	
KIMBERLY-CLARK WORLDWIDE, INC. 401 NORTH LAKE STREET			÷	STEPHENS, JACQUELINE F	
NEENAH, WI				ART UNIT	PAPER NUMBER
				3761	8
		٠		DATE MAILED: 04/05/2004	1
				<b>;</b>	

Please find below and/or attached an Office communication concerning this application or proceeding.

4	Application N .	Applicant(s)	
•	10/027,267	EVERHART ET AL.	
Office Action Summary	Examiner	Art Unit	
	Jacqueline F Stephens	3761	
The MAILING DATE of this communication	n appears on the cover sheet wi	th the correspondence address	
Period for Reply  A SHORTENED STATUTORY PERIOD FOR RETHE MAILING DATE OF THIS COMMUNICATION  - Extensions of time may be available under the provisions of 37 CF after SIX (6) MONTHS from the mailing date of this communication. If the period for reply specified above is less than thirty (30) days, If NO period for reply is specified above, the maximum statutory provided to the provided period for reply within the set or extended period for reply will, by some Any reply received by the Office later than three months after the rearned patent term adjustment. See 37 CFR 1.704(b).  Status	ON. FR 1.136(a). In no event, however, may a rin. a reply within the statutory minimum of thirt eriod will apply and will expire SIX (6) MON statute, cause the application to become AB	eply be timely filed  y (30) days will be considered timely.  THS from the mailing date of this communication.  ANDONED (35 U.S.C. § 133).	
<u>_</u>			
<ul> <li>1) Responsive to communication(s) filed on _</li> <li>2a) This action is FINAL.</li> <li>2b) Z</li> </ul>	This action is non-final.		
2a) ☐ This action is <b>FINAL</b> . 2b) ☐ 3) ☐ Since this application is in condition for all closed in accordance with the practice unc	owance except for formal matt		
Disposition of Claims			
4) ⊠ Claim(s) <u>1-63</u> is/are pending in the applicated 4a) Of the above claim(s) is/are with 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ⊠ Claim(s) <u>1-63</u> are subject to restriction and	ndrawn from consideration.		
Application Papers			
9) The specification is objected to by the Exam  10) The drawing(s) filed on is/are: a)  Applicant may not request that any objection to  Replacement drawing sheet(s) including the co  11) The oath or declaration is objected to by the	accepted or b) objected to the drawing(s) be held in abeyar orrection is required if the drawing	ce. See 37 CFR 1.85(a). (s) is objected to. See 37 CFR 1.121(d).	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for for a) All b) Some * c) None of:  1. Certified copies of the priority docur 2. Certified copies of the priority docur 3. Copies of the certified copies of the application from the International Bu * See the attached detailed Office action for a	ments have been received. ments have been received in A priority documents have been ureau (PCT Rule 17.2(a)).	pplication No received in this National Stage	
Attachment(s)			
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/S Paper No(s)/Mail Date	8) Paper No(s	summary (PTO-413) s)/Mail Date nformal Patent Application (PTO-152) 	

Application/Control Number: 10/027,267

Art Unit: 3761

## **DETAILED ACTION**

Page 2

## Election/Restrictions

1. This application contains claims directed to the following patentably distinct species of the claimed invention:

Species

- 1: therapeutic agent is formed with the cover
- 2: therapeutic agent is coupled to the cover surface
- 3: therapeutic agent is formed with the absorbent
- 4: therapeutic agent is coupled to the absorbent surface
- 5: therapeutic agent is positioned within the reservoir

In the event that applicant elects any one of species 1-5, applicant is required to further elect:

.Subspecies 1 – therapeutic agent is a liquid

- 2 therapeutic agent is an emulsion
- 3 therapeutic agent is a solid
- 4 therapeutic agent is a semi-solid
  - a) therapeutic agent is a gel
  - b) therapeutic agent is an ointment
  - c) therapeutic agent is a salve

2. The application contains claims directed to the following patentably distinct species of the claimed invention:

The pending claims recite several groups consisting of materials suitable for the therapeutic agent (i.e., aspirin, Lidocaine, Diltaizem, Dofetilide, Terbutaline, nitroglycerin, Celecoxib, vitamins, etc.). The applicant must identify which group of materials to prosecute.

The pending claims recite several methods in which the therapeutic agent is delivered to the labia of a wearer included by pressure, melting of a solid, melting of a semi-solid, and rupturing a capsule. The applicant must identify which method to prosecute.

3. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1, 42, and 55 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include

Art Unit: 3761

all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

4. A telephone call was made to Randall Fieldhack on 4/1/04 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 3761

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jacqueline F Stephens whose telephone number is (703) 308-8320. The examiner can normally be reached on Monday-Friday 9:00-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John Calvert can be reached on (703)305-1025. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Jacqueline F Stephens

Examiner

Art Unit 3761

April 1, 2004